Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0081 vs ReoPro in High Risk PCI
NCT01020383Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2009
- Primary completion
- Apr 2011
- Modality
- Nanobodies (VHH)
- Countries
- 7
01
Overview
A Phase 2 trial of caplacizumab in unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), stable angina, sponsored by Sanofi. Started Sep 2009; status: completed.
02
Drugs
caplacizumab
03
Conditions
unstable anginanon-ST segment elevation myocardial infarction (NSTEMI)stable angina
Beyond the preview
Go deeper on NCT01020383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01020383.